Breast Cancer | Oncology Updates

Centered on Breast Cancer, the sessions explored recent breakthroughs in treatment, therapies, and cutting-edge research advancements

About Event

The 3rd Oncology Updates, 29th March 2024, concentrated on Breast Cancer, offering in-depth discussions on recent breakthroughs in treatment. Experts explored advancements in personalized care, emerging research, and innovative therapies shaping the future of Breast Cancer management.

Meetings : Series 3
Track : Breast Cancer
Type : Virtual Mode
Time : 05:00 PM to 9:00 PM IST
Organizing Secretary
Dr.Ghanashyam Biswas,
Medical Oncologist

Key Intakes

8 +
Duration
65
Faculty
1000 +
Delegates
23
Sessions

Event Videos

5:00 PM-5:05 PM (5 Mins)

Introduction and Context Setting for the webinar

Dr.Ghanashyam Biswas (MO)
5:05 PM-5:10 PM (5 Mins)

Quiz-1 Breast Cancer

Dr. Sourav Kumar Mishra (MO)
5:10 PM-5:25 PM (15 Mins)

Metastatic hormone receptor HR Positive breast cancer putting the best foot forward

Dr. Ravi Sekhar Patnaik (MO)
5:25 PM-5:40 PM (15 Mins)

Adjuvant Abemaciclib in high risk HR Positive Breast cancer

Dr. Jogamaya Pattnaik (MO)
5:40 PM-6:10 PM (30 Mins)

Treatment sequencing in HER2 Positive Metastatic breast cancer

Dr. Amish Vora (MO)
6:10 PM-6:25 PM (15 Mins)

Managing Brain Metastasis in breast cancer

Dr. Kanhu Charan Patro (RO)
6:25 PM-6:40 PM (15 Mins)

Comcapsy

Dr.Ghanashyam Biswas (MO)
6:40 PM-6:55 PM (15 Mins)

Neo Adjuvant carboplatin in triple negative breast cancer is a standard of care

Dr.Vivek Agarwal (MO)
6:55 PM-7:25PM (30 Mins)

HR Positive Breast Cancer

Dr. Sourav Kumar Mishra(MO)
7:25 PM-7:40 PM (15 Mins)

Can Assist- A diagnostic hand for EBC

Dr. Manjari Bakre
7:40 PM-7:55 PM (15 Mins)

TDXD is the 1st option in Her2 + MBC (with Brain mets) previously exposed to Trastuzumab

Dr. Manoj Mahajan (MO)
7:55 PM-8:25 PM (30 Mins)

Neoadjuvant approaches in Triple negative Breast Cancer

Dr. Asish Vijay Bakshi (MO)
8:25 PM-8:40 PM (15 Mins)

Evolving Trends in Management of HER2 positive mBC.

Dr. M V Chandrakant(MO)
8:40 PM-8:45 PM (5 Mins)

Breast Cancer

Dr. Garima Sarawgi(SO)
8:45 PM-8:50 PM (5 Mins)

Vote of Thanks

Dr. Sourav Kumar Mishra(MO)
For More Details View Agenda

About Event

The 1st Oncology Updates, 8th July 2023, centered on the latest breakthroughs in Breast and Lung Cancer treatments. Expert speakers shared insights on innovative therapies, clinical strategies, and emerging research shaping the future of cancer care.

Meetings : Series 1
Track : Breast Cancer
Type : Virtual Mode
Time : 05:00 PM to 09:00 PM IST
Organizing Secretary
Dr.Ghanashyam Biswas,
Medical Oncologist

Key Intakes

8 +
Duration
62
Faculty
600 +
Delegates
24
Sessions

Event Videos

5:00 PM-5:05 PM (5 Mins)

Introduction and Context Setting for the webinar

Dr. Ghanashyam Biswas (MO)
5:05 PM-5:10 PM (5 Mins)

Quiz Breast Cancer

Dr. Soumya Surath Panda (MO)
5:10 PM-5:25 PM (15 Mins)

ASCO Updates in Breast Cancer

Dr.Vikas Talreja (MO)
5:25 PM-5:40 PM (15 Mins)

Adjuvant CDK4/6 inhibitor in breast Cancer is a standard of care

Dr Prabhaja N Mohapatra (MO)
5:40 PM-5:55 PM (15 Mins)

Neo adjuvant and Adjuvant chemotherapy in TNBC –Recent Advances

Dr. Uma Dhangi (MO)
5:55 PM-6:15 PM (20 Mins)

Oncoprecise Risk Predictor ( Prosigna)

Dr. Devavrat Arya (MO)
6:15 PM-6:30 PM (15 Mins)

HER2 Low stands tall among all subsets (Sponsored Talk-Astrazeneca)

Dr Anil Tarigopula (PATH)
6:30 PM-6:55 PM (25 Mins)

Nuances in management of DCIS

Dr. Neha Choudhary(SO)
6:55 PM-7:05PM (10 Mins)

Hereditary Breast and Ovarian Cancer

Dr. Richi Khandelwal(Gynaec ONCO)
7:05 PM-7:15 PM (10 Mins)

Evolving landscape of CDK4/6i: Implications for Clinical Practice (For HR+/HER2- mBC Patients)

Dr Sashanka Shekhar Das (MO)
7:15 PM-7:30 PM (15 Mins)

Emerging Landscape of HER2 Low: A Novel Entity in clinical practice

Dr. Ghanashyam Biswas (MO)
7:30 PM7:45 PM (15 Mins)

ASCO Updates in Lung cancer

Dr. Chetan Deshmukh (MO)
7:45 PM8:10 PM (25 Mins)

Neo Adjuvant IO and Adjuvant IO therapy in Early lung cancer

Dr. Prasad Narayanan(MO)
8:10 PM8:25 PM (15 Mins)

Adjuvant Osimertinib in Resected Lung Cancer – Fair or Unfair

Dr. Naresh Somani (MO)
8:25 PM8:40 PM (15 Mins)

Management of mNSCLC and Role of Tecentriq

Dr. Sourav Kumar Mishra (MO)
8:40 PM9:00 PM (20 Mins)

Spotlighting Non-EGFR mutated NSCLC’s (Non-small cell Lung carcinoma)

Dr. Richa Nathani (Path)
9:00 PM–9:05 PM (5 Mins)

Quiz Lung Cancer

Dr. Ghanashyam Biswas (MO)
9:05 PM– 9:10PM

Vote of thanks

Dr. Soumya Surath Panda (MO)
For More Details View Agenda